AU2012338362B2 - Tricyclic compounds, compositions comprising them and uses thereof - Google Patents

Tricyclic compounds, compositions comprising them and uses thereof Download PDF

Info

Publication number
AU2012338362B2
AU2012338362B2 AU2012338362A AU2012338362A AU2012338362B2 AU 2012338362 B2 AU2012338362 B2 AU 2012338362B2 AU 2012338362 A AU2012338362 A AU 2012338362A AU 2012338362 A AU2012338362 A AU 2012338362A AU 2012338362 B2 AU2012338362 B2 AU 2012338362B2
Authority
AU
Australia
Prior art keywords
branched
straight
halogen
disease
nitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012338362A
Other languages
English (en)
Other versions
AU2012338362A1 (en
Inventor
Shmuel Ben-Sasson
Arie Dagan
Sharon PERLES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of AU2012338362A1 publication Critical patent/AU2012338362A1/en
Application granted granted Critical
Publication of AU2012338362B2 publication Critical patent/AU2012338362B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012338362A 2011-11-15 2012-11-15 Tricyclic compounds, compositions comprising them and uses thereof Active AU2012338362B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161559964P 2011-11-15 2011-11-15
US61/559,964 2011-11-15
US201261603508P 2012-02-27 2012-02-27
US61/603,508 2012-02-27
PCT/IL2012/050461 WO2013072915A1 (en) 2011-11-15 2012-11-15 Tricyclic compounds, compositions comprising them and uses thereof

Publications (2)

Publication Number Publication Date
AU2012338362A1 AU2012338362A1 (en) 2014-05-29
AU2012338362B2 true AU2012338362B2 (en) 2017-05-18

Family

ID=48429067

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012338362A Active AU2012338362B2 (en) 2011-11-15 2012-11-15 Tricyclic compounds, compositions comprising them and uses thereof

Country Status (25)

Country Link
US (1) US9447040B2 (enExample)
EP (1) EP2802320B1 (enExample)
JP (1) JP6087367B2 (enExample)
KR (1) KR101986272B1 (enExample)
CN (1) CN104010636B (enExample)
AU (1) AU2012338362B2 (enExample)
BR (1) BR112014011641B1 (enExample)
CA (1) CA2855759C (enExample)
CL (1) CL2014001278A1 (enExample)
CO (1) CO7020909A2 (enExample)
DK (1) DK2802320T3 (enExample)
ES (1) ES2729713T3 (enExample)
HR (1) HRP20190927T1 (enExample)
HU (1) HUE043827T2 (enExample)
IN (1) IN2014CN03610A (enExample)
MX (1) MX347570B (enExample)
PE (1) PE20141940A1 (enExample)
PH (1) PH12014501061B1 (enExample)
PL (1) PL2802320T3 (enExample)
PT (1) PT2802320T (enExample)
RU (1) RU2624446C9 (enExample)
SG (1) SG11201402258UA (enExample)
SI (1) SI2802320T1 (enExample)
WO (1) WO2013072915A1 (enExample)
ZA (1) ZA201404065B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016020919A1 (en) 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof
WO2016203468A1 (en) * 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
JP2023503769A (ja) * 2019-09-15 2023-02-01 ラジエル セラピューティクス エルティーディー． 固形腫瘍の処置のための組成物
EP4096653A4 (en) * 2020-01-28 2024-02-28 Raziel Therapeutics Ltd. Compositions for the treatment of angiolipoma
WO2022058792A1 (en) * 2020-09-16 2022-03-24 Raziel Therapeutics Ltd. Compositions for the treatment of fat related conditions and disorders
AU2021344871A1 (en) * 2020-09-16 2023-05-25 Raziel Therapeutics Ltd. Compositions and methods for the treatment of lipid-related disorders
WO2022234337A2 (en) * 2021-05-06 2022-11-10 Raziel Therapeutics Ltd. Crystalline carbazole derivative
CN117956990A (zh) * 2021-07-28 2024-04-30 拉结尔治疗有限公司 用于治疗脂肪瘤疼痛的组合物和方法
CN115073374B (zh) * 2022-06-14 2023-10-27 五邑大学 一种α-葡萄糖苷酶抑制剂及其制备方法和应用
KR20250152557A (ko) * 2022-11-07 2025-10-23 라지엘 테라퓨틱스 리미티드 결정질 카바졸 유도체 및 이의 제조 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2676966A (en) * 1951-04-04 1954-04-27 Searle & Co Quaternary salts of 9-carbazolealkylamines and 10-acridanalkylamines and methods forpreparing same
GB832568A (en) * 1956-08-03 1960-04-13 Clin Byla Ets Heterocyclic compounds and production thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2590125A (en) * 1952-03-25 Quaternary-ammonium alkyl
US2676971A (en) * 1951-04-21 1954-04-27 Searle & Co Quaternary ammonium derivatives of aminoalkylxanthenes and aminoalkylthiaxanthenes
FR1186832A (fr) * 1956-08-03 1959-09-02 Etablissements Clin-Byla Composés hétérocycliques dérivés du pyrrol et des benzopyrrols et leur fabrication
US2930798A (en) * 1956-08-03 1960-03-29 Clin Byla Ets 3-alkanoyl 1-tertiary-amino-alkyl indol oximes and production thereof
GB866418A (en) * 1958-01-25 1961-04-26 Bayer Ag Phenoxazine derivatives
US3836587A (en) * 1969-11-17 1974-09-17 American Cyanamid Co Organo phosphonium salts
AR205331A1 (es) * 1972-07-24 1976-04-30 Hoffmann La Roche Procedimiento para la preparacion de carbazoles
FR2691459B1 (fr) * 1992-05-25 1995-06-09 Adir Nouveaux derives de la phenothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH11504905A (ja) 1995-05-05 1999-05-11 ノボ ノルディスク アクティーゼルスカブ 新規複素環の化学
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
EP1094063A1 (en) 1999-10-18 2001-04-25 Applied Research Systems ARS Holding N.V. 9-(Piperazinylalkyl)carbazoles as Bax-modulators
GB9925880D0 (en) 1999-11-01 1999-12-29 British Tech Group Int B-Carboline derivatives
DE60218155D1 (de) * 2001-03-28 2007-03-29 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
WO2003027084A1 (en) * 2001-09-25 2003-04-03 Dr. Reddy's Laboratories Ltd. Improved process for the preparation of optically active phenoxazine derivatives as antidiabetic agents
US7428091B2 (en) * 2004-11-15 2008-09-23 Gentex Corporation Electrochromic compounds and associated media and devices
WO2007079239A2 (en) 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
US20090317372A1 (en) * 2008-06-20 2009-12-24 Zoltan Kiss Small molecules for the reduction of high blood glucose level
UA107652C2 (en) * 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
US8362277B2 (en) * 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8604074B2 (en) 2009-01-09 2013-12-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2012006419A2 (en) * 2010-07-07 2012-01-12 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2676966A (en) * 1951-04-04 1954-04-27 Searle & Co Quaternary salts of 9-carbazolealkylamines and 10-acridanalkylamines and methods forpreparing same
GB832568A (en) * 1956-08-03 1960-04-13 Clin Byla Ets Heterocyclic compounds and production thereof

Also Published As

Publication number Publication date
RU2624446C2 (ru) 2017-07-04
KR20140099492A (ko) 2014-08-12
RU2014119711A (ru) 2015-12-27
MX347570B (es) 2017-05-02
AU2012338362A1 (en) 2014-05-29
CA2855759A1 (en) 2013-05-23
PE20141940A1 (es) 2014-12-18
KR101986272B1 (ko) 2019-06-05
PH12014501061B1 (en) 2018-12-12
CL2014001278A1 (es) 2014-12-26
BR112014011641A2 (pt) 2017-05-02
EP2802320A1 (en) 2014-11-19
EP2802320B1 (en) 2019-02-20
ES2729713T3 (es) 2019-11-05
CN104010636A (zh) 2014-08-27
MX2014005765A (es) 2015-09-23
CO7020909A2 (es) 2014-08-11
PT2802320T (pt) 2019-06-17
JP2014533264A (ja) 2014-12-11
IN2014CN03610A (enExample) 2015-10-09
CA2855759C (en) 2020-03-10
PL2802320T3 (pl) 2019-09-30
SI2802320T1 (sl) 2019-08-30
SG11201402258UA (en) 2014-06-27
PH12014501061A1 (en) 2014-06-23
ZA201404065B (en) 2015-11-25
EP2802320A4 (en) 2015-08-12
US9447040B2 (en) 2016-09-20
US20140329877A1 (en) 2014-11-06
BR112014011641B1 (pt) 2020-10-27
DK2802320T3 (da) 2019-05-27
HUE043827T2 (hu) 2019-09-30
HRP20190927T1 (hr) 2019-08-23
CN104010636B (zh) 2017-04-12
RU2624446C9 (ru) 2018-04-04
WO2013072915A1 (en) 2013-05-23
JP6087367B2 (ja) 2017-03-01

Similar Documents

Publication Publication Date Title
AU2012338362B2 (en) Tricyclic compounds, compositions comprising them and uses thereof
JP5596680B2 (ja) 経口抗がん製剤
MXPA03006597A (es) Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad.
BR112019026450A2 (pt) imidazopirimidinas substituídas diazabicíclicas e seu uso para o tratamento de transtornos respiratórios
US11046684B2 (en) Compound for selectively inhibiting kinase and use thereof
JPS636058B2 (enExample)
CN105142644A (zh) 奥那司酮多晶型形式和使用方法
ES2615052T3 (es) Compuesto de benzotiazolona
WO2016020919A1 (en) Compositions comprising tricyclic compounds, and uses thereof
EP4114408A1 (fr) Dérivés de nicotinamide mononucléotide et de bis-nicotinamide dinucléotide pour le traitement de l'arythmie
US9102636B2 (en) Analgesic compounds, compositions, and uses thereof
JP6610793B2 (ja) 環状アミン誘導体の結晶及びその医薬用途
JP7498504B2 (ja) 脳神経または心臓保護剤としてのアミノチオール系化合物の使用
JP6173352B2 (ja) 筋萎縮性側索硬化症の治療方法
WO2022125613A1 (en) Phosphonates as inhibitors of enpp1 and cdnp
JP5819865B2 (ja) 小腸刷子縁膜ナトリウム／リン酸塩共−輸送のアリールフルオロホスフェート阻害剤
BR112016009918B1 (pt) Composto apresentando maior inibição da atividade da proteína quinase g, seu uso e seu método de preparação, e composição farmacêutica
WO2019233366A1 (zh) 选择性a 2a受体拮抗剂
US20260001872A1 (en) Benzisothiazole compound and application thereof, and pharmaceutical composition and application thereof
CN120698929A (zh) 一种联苯烯烃类化合物及其药物组合物和应用
CN106977500A (zh) 一种用于治疗脑梗塞的药物及其制备方法
WO2025140275A1 (zh) 取代吡唑啉偶氮衍生物的磷酸酯化合物或其可药用盐
KR20220123404A (ko) Cns 장애를 치료하기 위한 화합물 및 조성물
WO2015103901A1 (zh) 硬脂酰氨基酸盐及其制备方法和应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)